Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence

Summary

This project will examine effects of bupropion extended release (XL) at a dose of 300mg/day for cocaine abstinence among persons receiving methadone for the treatment of opioid use disorder. Participants also earned financial incentives for providing urine samples that tested negative for cocaine. Bupropion was examined for this purpose because of its previously demonstrated efficacy and safety as well as its pharmacological actions at dopamine systems. Participants were randomly assigned to bupropion XL vs. placebo and received different incentive schedules depending on whether they demonstrated abstinence from cocaine early in the study. Outcomes were tracked over a 6-month time frame and the overarching hypothesis was that bupropion (as compared to placebo) would increase the number of urine samples testing negative for cocaine, independent of whether participants demonstrated abstinence from cocaine early in the study.

Conditions

• Substance Abuse
• Cocaine Dependence

Interventions

DRUG

Placebo

Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.

DRUG

Bupropion XL

Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.

BEHAVIORAL

Abstinence Initiation

Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.

BEHAVIORAL

Relapse Prevention

Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• Johns Hopkins University

  lead OTHER

Principal Investigators

• Kelly Dunn, Ph.D., MBA · Johns Hopkins University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2014-07-31

Primary Completion

2020-05-31

Completion

2021-01-31

Countries

• United States

Study Locations